prednisone has been researched along with Community Acquired Infection in 14 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the influence of prednisone on inflammatory biomarkers in a previous multicenter, randomized, placebo-controlled trial that compared a 7-day treatment course of 50-mg prednisone to placebo in patients hospitalized with community-acquired pneumonia." | 9.41 | Influence of Prednisone on Inflammatory Biomarkers in Community-Acquired Pneumonia: Secondary Analysis of a Randomized Trial. ( Blum, CA; Blum, MR; Briel, M; Cesana-Nigro, N; Christ-Crain, M; Mueller, B; Raess, N; Rodondi, N; Schaedelin, S; Schuetz, P; Urwyler, SA; Winzeler, B, 2021) |
| "Prednisone treatment for 7 days in patients with community-acquired pneumonia admitted to hospital shortens time to clinical stability without an increase in complications." | 9.20 | Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. ( Arici, B; Baumgartner, C; Bingisser, R; Blum, CA; Briel, M; Burki, D; Christ-Crain, M; Drozdov, D; Duplain, H; Elsaesser, H; Mueller, B; Nigro, N; Refardt, J; Rodondi, N; Schuetz, P; Suter-Widmer, I; Tarr, P; Thomann, R; Ullmer, E; Urwyler, SA; Winzeler, B; Wirz, S; Zimmerli, W, 2015) |
| " We investigated the influence of prednisone on inflammatory biomarkers in a previous multicenter, randomized, placebo-controlled trial that compared a 7-day treatment course of 50-mg prednisone to placebo in patients hospitalized with community-acquired pneumonia." | 5.41 | Influence of Prednisone on Inflammatory Biomarkers in Community-Acquired Pneumonia: Secondary Analysis of a Randomized Trial. ( Blum, CA; Blum, MR; Briel, M; Cesana-Nigro, N; Christ-Crain, M; Mueller, B; Raess, N; Rodondi, N; Schaedelin, S; Schuetz, P; Urwyler, SA; Winzeler, B, 2021) |
| "We have recently shown that adjunct prednisone shortens the time taken to reach clinical stability (time to clinical stability, TTCS) in patients with community-acquired pneumonia (CAP)." | 5.22 | Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients. ( Blum, CA; Christ-Crain, M; Mueller, B; Nigro, N; Popovic, M; Schuetz, P, 2016) |
| "Prednisone treatment for 7 days in patients with community-acquired pneumonia admitted to hospital shortens time to clinical stability without an increase in complications." | 5.20 | Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. ( Arici, B; Baumgartner, C; Bingisser, R; Blum, CA; Briel, M; Burki, D; Christ-Crain, M; Drozdov, D; Duplain, H; Elsaesser, H; Mueller, B; Nigro, N; Refardt, J; Rodondi, N; Schuetz, P; Suter-Widmer, I; Tarr, P; Thomann, R; Ullmer, E; Urwyler, SA; Winzeler, B; Wirz, S; Zimmerli, W, 2015) |
| "1007/s00125-016-4091-4 ) have conducted a subanalysis within a randomised controlled trial of prednisone therapy for community-acquired pneumonia." | 3.83 | Steroid-induced hyperglycaemia in hospitalised patients: does it matter? ( Cheung, NW, 2016) |
| "Prednisone treatment modified circulatory NET levels and was associated with beneficial outcome." | 2.87 | Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial. ( Baumgartner, C; Blum, CA; Christ-Crain, M; Ebrahimi, F; Giaglis, S; Hahn, S; Hasler, P; Kutz, A; Mueller, B; Schuetz, P; van Breda, SV, 2018) |
| "Patients with underlying COPD received systemic corticosteroids (n = 10), while non-COPD patients (n = 10) presenting with CAP alone formed the control group." | 2.73 | Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. ( Capelli, B; Cerutti, B; Domenighetti, G; Duchini, F; Lepori, M; Perren, A; Senn, V, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Raess, N | 1 |
| Schuetz, P | 8 |
| Cesana-Nigro, N | 1 |
| Winzeler, B | 4 |
| Urwyler, SA | 4 |
| Schaedelin, S | 1 |
| Rodondi, N | 4 |
| Blum, MR | 2 |
| Briel, M | 4 |
| Mueller, B | 8 |
| Christ-Crain, M | 8 |
| Blum, CA | 8 |
| Ebrahimi, F | 1 |
| Giaglis, S | 1 |
| Hahn, S | 1 |
| Baumgartner, C | 2 |
| Kutz, A | 1 |
| van Breda, SV | 1 |
| Hasler, P | 1 |
| Nigro, N | 4 |
| Arici, B | 2 |
| Refardt, J | 2 |
| Coslovsky, M | 1 |
| Lee, E | 1 |
| Kim, TM | 1 |
| Lim, Y | 1 |
| Jeon, YK | 1 |
| Go, H | 1 |
| Kim, CW | 1 |
| Heo, DS | 1 |
| Suter-Widmer, I | 2 |
| Bingisser, R | 2 |
| Zimmerli, W | 2 |
| Ullmer, E | 2 |
| Elsaesser, H | 2 |
| Tarr, P | 2 |
| Wirz, S | 2 |
| Thomann, R | 2 |
| Hofmann, E | 1 |
| Duplain, H | 2 |
| Burki, D | 2 |
| Catteeuw, J | 1 |
| Koegelenberg, CFN | 1 |
| Bruwer, JW | 1 |
| Sissolak, G | 1 |
| Schroeter, L | 1 |
| Mohamed, N | 1 |
| Irusen, EM | 1 |
| Drozdov, D | 1 |
| Birocchi, S | 1 |
| Cernuschi, G | 1 |
| Rasche, K | 1 |
| Nitschmann, S | 1 |
| Wirz, SA | 1 |
| Albrich, WC | 1 |
| Noppen, C | 1 |
| Tarr, PE | 1 |
| Popovic, M | 1 |
| Cheung, NW | 1 |
| Perren, A | 1 |
| Cerutti, B | 1 |
| Lepori, M | 1 |
| Senn, V | 1 |
| Capelli, B | 1 |
| Duchini, F | 1 |
| Domenighetti, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Short-Term Prednisone Therapy on C-reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers[NCT05916586] | 120 participants (Anticipated) | Interventional | 2023-08-11 | Recruiting | |||
| Corticosteroid Treatment for Community-Acquired Pneumonia A Randomized, Double-blind Study- The STEP Trial[NCT00973154] | Phase 3 | 800 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study[NCT05354778] | 180 participants (Anticipated) | Interventional | 2022-10-16 | Recruiting | |||
| Evaluating the Impact of a New Model of Care Designed to Improve Evidence-based Management of Community-acquired Pneumonia[NCT02835040] | 814 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 trials available for prednisone and Community Acquired Infection
| Article | Year |
|---|---|
Influence of Prednisone on Inflammatory Biomarkers in Community-Acquired Pneumonia: Secondary Analysis of a Randomized Trial.
Topics: Aged, 80 and over; Analysis of Variance; Biomarkers, Pharmacological; C-Reactive Protein; Community- | 2021 |
Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Biomarkers; Community-Acquired Infections; Extracell | 2018 |
Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial.
Topics: Adult; Community-Acquired Infections; Cosyntropin; Decision Making; Female; Glucocorticoids; Humans; | 2019 |
Cytokines and Cortisol - predictors of treatment response to corticosteroids in community-acquired pneumonia?
Topics: Aged; Aged, 80 and over; Chemokine CCL2; Community-Acquired Infections; Double-Blind Method; Female; | 2019 |
Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clinical Protocols; Commun | 2014 |
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infecti | 2015 |
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infecti | 2015 |
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infecti | 2015 |
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infecti | 2015 |
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infecti | 2015 |
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infecti | 2015 |
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infecti | 2015 |
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infecti | 2015 |
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infecti | 2015 |
Adjunct prednisone therapy for patients with community-acquired pneumonia.
Topics: Adult; Community-Acquired Infections; Double-Blind Method; Glucocorticoids; Hospitalization; Humans; | 2015 |
[Community-acquired pneumonia. New treatment concepts].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Community-Acquired Infections; Humans; Pneumonia, B | 2015 |
Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia.
Topics: Administration, Intravenous; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Bacterial Agents | 2016 |
Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Community-Acquired Infections; Diabetes Mellitus; | 2016 |
Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; C-Reactive Protein; Calcitonin; Calcitonin Ge | 2008 |
3 other studies available for prednisone and Community Acquired Infection
| Article | Year |
|---|---|
Histologic transformation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; | 2013 |
A 54-year-old man referred with nonresolving pneumonia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Community-Ac | 2014 |
Steroid-induced hyperglycaemia in hospitalised patients: does it matter?
Topics: Community-Acquired Infections; Diabetes Mellitus; Glucocorticoids; Hospitalization; Humans; Hypergly | 2016 |